Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Possible marker of severe COVID-19 cases
July/August 2020
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—Researchers at the University of Paris leveraged mass cytometry and software by Fluidigm—including the Fluidigm Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter anaylsis software—to discover a key change in the immune systems of those with severe cases of COVID-19. Fifty patients with different levels of disease severity were tested eight to 12 days after onset of symptoms and in the absence of anti-inflammatory therapy. Testing and analysis revealed that critically ill patients presented with significant impairment of type I interferon activity, and it is thought that such patients might see some benefit form anti-inflammatory therapies that target IL-6 or TNF-a inflammatory cytokines.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.